Effect of intermittent oral administration of ponazuril on experimental Sarcocystis neurona infection of horses

American Journal of Veterinary Research

Volumn 69, Issue 3, 2008, Pages 396-402

  MacKay, Robert J ^a   Tanhauser, Susan T ^a,f   Gillis, Karen D ^a   Mayhew, Ian G ^b,c,d   Kennedy, Tom J ^e  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c BAYER CORPORATION   (United States)

^d MASSEY UNIVERSITY   (New Zealand)

^e Farnam Companies Inc   (United States)

^f Newberry Equine Veterinary Service   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPROTOZOAL AGENT; IMMUNOGLOBULIN G; PONAZURIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG INTERMITTENT THERAPY; ENCEPHALOMYELITIS; FEMALE; HISTOPATHOLOGY; HORSE DISEASE; INOCULATION; MALE; NONHUMAN; PROTOZOAL INFECTION; SARCOCYSTIS NEURONA; SERODIAGNOSIS; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, PROTOZOAN; BLOTTING, WESTERN; BRAIN; COCCIDIOSTATS; ENCEPHALOMYELITIS; FEMALE; HISTOCYTOCHEMISTRY; HORSE DISEASES; HORSES; MALE; SARCOCYSTIS; SARCOCYSTOSIS; TRIAZINES;

ANIMALIA; EQUIDAE; PROTOZOA; SARCOCYSTIS NEURONA;

EID: 41049103851     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.69.3.396     Document Type: Article

References (46)

1. Equine '98. Equine protozoal myeloencephalitis (EPM) in the US. #N312.0501. Fort Collins, Colo: USDA, APHIS, Veterinary Services, Centers for Epidemiology and Animal Health, National Animal Health Monitoring System, 2001.
2. Bentz BG, Ealey KA, Morrow J, et al. Seroprevalence of antibodies to Sarcocystis neurona in equids residing in Oklahoma. J Vet Diagn Invest 2003;15:597-600.
3. Tillotson K, McCue PM, Granstrom DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in northern Colorado. J Equine Vet Sci 1999;122-126.
4. Cheadle MA, Yowell CA, Sellon DC, et al. The striped skunk (Mephitis mephitis) is an intermediate host for Sarcocystis nurona. Int J Parasitol 2001;31:843-849.
5. Cheadle MA, Tanhauser SM, Dame JB, et al. The nine-banded armadillo ( Dasypus novemcinctus) is an intermediate host for Sarcocystis neurona. Int J Parasitol 2001;31:330-335.
6. Dubey JP, Saville WJ, Lindsay DS, et al. Completion of the life cycle of Sarcocystis neurona. J Parasitol 2000;86:1276-1280.
7. Fenger CK, Granstrom DE, Langemeier JL, et al. Identification of opossums (Didelphis virginiana) as the putative definitive host of Sarcocystis neurona. J Parasitol 1995;81:916-919.
8. Dubey JP. Migration and development of Sarcocystis neurona in tissues of interferon gamma knockout mice fed sporocysts from a naturally infected opossum. Vet Parasitol 2001;95:341-351.
9. Mullaney T, Murphy AJ, Kiupel M, et al. Evidence to support horses as natural intermediate hosts for Sarcocystis neurona. Vet Parasitol 2005;133:27-36.
10. Dubey JP, Saville WJ, Stanek JF, et al. Sarcocystis neurona infections in raccoons (Procyon lotor): evidence for natural infection with sarcocysts, transmission of infection to opossums ( Didelphis virginiana), and experimental induction of neurologic disease in raccoons. Vet Parasitol 2001;100:117-129.
11. Dubey JP, Lindsay DS. Isolation in immunodeficient mice of Sarcocystis neurona from opossum (Didelphis virginiana) faeces, and its differentiation from Sarcocystis falcatula. Int J Parasitol 1998;28:1823-1828.
12. Cutler TJ, MacKay RJ, Ginn PE, et al. Are Sarcocystis neurona and Sarcocystis falcatula synonymous? A horse infection challenge. J Parasitol 1999;85:301-305.
13. Cutler TJ, MacKay RJ, Ginn PE, et al. Immunoconversion against Sarcocystis neurona in normal and dexamethasone-treated horses challenged with S. neurona sporocysts. Vet Parasitol 2001;95:197-210.
14. Fenger CK, Granstrom DE, Gajadhar AA, et al. Experimental induction of equine protozoal myeloencephalitis in horses using Sarcocystis sp. sporocysts from the opossum (Didelphis virginiana). Vet Parasitol 1997;68:199-213.
15. Saville WJ, Stich RW, Reed SM, et al. Utilization of stress in the development of an equine model for equine protozoal myeloencephalitis. Vet Parasitol 2001;95:211-222.
16. Saville WJ, Sofaly CD, Reed SM, et al. An equine protozoal myeloencephalitis challenge model testing a second transport after inoculation with Sarcocystis neurona sporocysts. J Parasitol 2004;90:1406-1410.
17. Sofaly CD, Reed SM, Gordon JC, et al. Experimental induction of equine protozoan myeloencephalitis (EPM) in the horse: effect of Sarcocystis neurona sporocyst inoculation dose on the development of clinical neurologic disease. J Parasitol 2002;88:1164-1170.
18. Murphy JE, Marsh AE, Reed SM, et al. Development and evaluaLion of a Sarcocystis neurona-specific IgM capture enzyme-linked immunosorbent assay. J Vet Intern Med 2006;20:322-328.
19. Furr M, McKenzie H, Saville WJ, et al. Prophylactic administration of ponazuril reduces clinical signs and delays seroconversion in horses challenged with Sarcocystis neurona. J Parasitol 2006;92:637-643.
20. Saville WJ, Reed SM, Morley PS, et al. Analysis of risk factors for the development of equine protozoal myeloencephalitis in horses. J Am Vet Med Assoc 2000;217:1174-1180.
21. Marsh AE, Lakritz J, Johnson PJ, et al. Evaluation of immune responses in horses immunized using a killed Sarcocystis neurona vaccine. Vet Ther 2004;5:34-42.
22. Furr M, Kennedy T, MacKay R, et al. Efficacy of ponazuril 15% oral paste as a treatment for equine protozoal myeloencephalitis. Vet Ther 2001;2:215-222.
23. Franklin RP, MacKay RJ, Gillis KD, et al. Effect of a single dose of ponazuril on neural infection and clinical disease in Sarcocystis neurona-challenged interferon-gamma knockout mice. Vet Parasitol 2003;114:123-130.
24. Tanhauser SM, Yowell CA, Cutler TJ, et al. Multiple DNA markers differentiate Sarcocystis neurona and Sarcocystis falcatula. J Parasitol 1999;85:221-228.
25. Mayhew IG. Neurologic evaluation. In: Large animal neurology: a handbook for veterinary clinicians. Philadelphia: WB Saunders Co, 1978;15-47.
26. Andrews FM, Maddux JM, Faulk D. Total protein, albumin quotient, IgG and IgG index determinations for horse cerebrospinal fluid. Prog Vet Neurol 1996;1:197-204.
27. Mayhew IG, de Lahunta A. Neuropathology. Cornell Vet 1978;68(suppl 6):106-147.
28. Carlson GP, Morris DD. Collection of samples and interpretation of laboratory tests. In: Smith BP, ed. Large animal internal medicine. 3rd ed. St Louis: Mosby, 2002;387-440.
29. Kennedy T, Campbell J, Selzer V Safety of ponazuril 15% oral paste in horses. Vet Ther 2001;2:223-231.
30. Lindsay DS, Dubey JP, Kennedy TJ. Determination of the activity of ponazuril against Sarcocystis neurona in cell cultures. Vet Parasitol 2000;92:165-169.
31. Furr M, Kennedy T. Cerebrospinal fluid and serum concentrations of ponazuril in horses. Vet Ther 2001;2:232-237.
32. Saville WJ, Reed SM, Granstrom DE, et al. Seroprevalence of antibodies to Sarcocystis neurona in horses residing in Ohio. J Am Vet Med Assoc 1997;210:519-524.
33. Ellison SP, Greiner E, Brown KK, et al. Experimental infection of horses with culture-derived Sarcocystis neurona merozoites as a model for equine protozoal myeloencephalitis. Intern J Appl Res Vet Med 2004;2:79-89.
34. Rossano MG, Schott HC, Murphy AJ, et al. Parasitemia in an immunocompetent horse experimentally challenged with Sarcocystis neurona sporocysts. Vet Parasitol 2005;127:3-8.
35. Dubey JP, Speer CA, Fayer R. General biology. In: Dubey JP, Speer CA, Fayer R, eds. Sarcocystosis of animals and man. Boca Raton, Fla: CRC Press Inc, 1989;1-207.
36. Miller MM, Sweeney CR, Russell GE, et al. Effects of blood contamination of cerebrospinal fluid on western blot analysis for detection of antibodies against Sarcocystis neurona and on albumin quotient and immunoglobulin G index in horses. J Am Vet Med Assoc 1999;215:67-71.
37. Daft BM, Barr BC, Gardner IA, et al. Sensitivity and specificity of western blot testing of cerebrospinal fluid and serum for diagnosis of equine protozoal myeloencephalitis in horses with and without neurologic abnormalities. J Am Vet Med Assoc 2002;221:1007-1013.
38. Witonsky S, Morrow JK, Leger C, et al. Sarcocystis neurona-specific immunoglobulin G in the serum and cerebrospinal fluid of horses administered S neurona vaccine. J Vet Intern Med 2004;18:98-103.
39. Furr M. Antigen-specific antibodies in cerebrospinal fluid after intramuscular injection of ovalbumin in horses. J Vet Intern Med 2002;16:588-592.
40. Andrews FM, Geiser DR, Sommardahl CS, et al. Albumin quotient, IgG concentration, and IgG index determinations in cerebrospinal fluid of neonatal foals. Am J Vet Res 1994;55:741-745.
41. Reiber H. Cerebrospinal fluid - physiology, analysis and interpretation of protein patterns for diagnosis of neurological diseases. Mult Scler 1998;4:99-107.
42. Tumani H, Nolker G, Reiber H. Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. Neurology 1995;45:1663-1670.
43. Dorta-Contreras AJ, Reiber H. Intrathecal synthesis of immunoglobulins in eosinophilic meningoencephalitis due to Angiostrongylus cantonensis. Clin Diagn Lab Immunol 1998;5:452-455.
44. Contini C, Fainardi E, Cultrera R, et al. Advanced laboratory techniques for diagnosing Toxoplasma gondii encephalitis in AIDS patients: significance of intrathecal production and comparison with PCR and ECL-western blotting. J Neuroimmunol 1998;92:29-37.
45. Lejon V, Reiber H, Legros D, et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 2003;187:1475-1483.
46. Heskett KA, MacKay RJ. Antibody index and specific antibody quotient in horses after intragastric administration of Sarcocystis neurona sporocysts. Am J Vet Res 2008;69:403-409.